Loading...
•
Jun 30
Johnson & Johnson Q2 2025 Earnings Report
Johnson & Johnson reported solid Q2 2025 results with higher revenue and raised full-year guidance.
Key Takeaways
Johnson & Johnson delivered strong Q2 2025 results, with revenue growth driven by MedTech and oncology products. The company reported higher net income and raised its full-year sales and EPS guidance.
Revenue grew 5.8% year-over-year to $23.7B
Net income increased 18.2% to $5.54B
Adjusted EPS came in at $2.77, slightly below last year’s $2.82
Raised full-year sales and EPS guidance citing MedTech strength and oncology pipeline momentum
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson Revenue by Segment
Johnson & Johnson Revenue by Geographic Location
Revenue by Segment
Innovative Medicine Revenue
CapyFin.comMedTech Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Johnson & Johnson raised its full-year sales and EPS guidance, citing strong MedTech performance and oncology pipeline momentum.
Positive Outlook
- Raised full-year reported sales guidance midpoint by $2B to 5.4% growth
- Raised full-year adjusted operational EPS midpoint to $10.68
- Strong MedTech performance, particularly in cardiovascular and surgical products
- Positive oncology pipeline developments, including approvals for IMAAVY and CARVYKTI data
- Favorable foreign exchange trends supported guidance increase
Challenges Ahead
- Adjusted net earnings slightly declined year-over-year
- Adjusted EPS fell to $2.77 from $2.82 last year
- Ongoing impact from STELARA declines in Immunology
- Continued pricing pressures in certain international markets
- Lower free cash flow compared to $7.5B last year
Revenue & Expenses
Visualization of income flow from segment revenue to net income